Free Trial
→ Chaotic markets? No worries! (From WealthPress) (Ad)
NASDAQ:ALZN

Alzamend Neuro 3/10/2025 Earnings Report

Alzamend Neuro logo
$2.92 -0.12 (-3.95%)
As of 02:02 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
ProfileEarnings HistoryForecast

Alzamend Neuro EPS Results

Actual EPS
-$1.71
Consensus EPS
-$2.61
Beat/Miss
Beat by +$0.90
One Year Ago EPS
N/A

Alzamend Neuro Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Alzamend Neuro Announcement Details

Quarter
Date
3/10/2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Alzamend Neuro's next earnings date is estimated for Tuesday, July 29, 2025, based on past reporting schedules.

Conference Call Resources

Alzamend Neuro Earnings Headlines

Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule
June 16, 2025 | globenewswire.com
Alzamend Neuro (NASDAQ:ALZN) Stock Rating Upgraded by Wall Street Zen
June 14, 2025 | americanbankingnews.com
A new rule goes live in July — and the banks are quietly cashing in
A major change is quietly going into effect this July — and Wall Street is already positioning for it. Big Banks have found a way to use a new asset as if it were cash. Not stocks. Not bonds. Not even the U.S. dollar. They now trust this asset more than the traditional financial system itself.
June 23, 2025 | American Alternative (Ad)
Alzamend Neuro Stock Rockets On Dosing Of First Human Patient With Lithium-Delivery System AL001 In Phase II Study: Retail’s Thrilled
May 29, 2025 | msn.com
Alzamend Neuro Stock Doubles After Dosing of First Patient in Clinical Trial
May 29, 2025 | marketwatch.com
Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital
May 29, 2025 | globenewswire.com
See More Alzamend Neuro Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Alzamend Neuro? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alzamend Neuro and other key companies, straight to your email.

About Alzamend Neuro

Alzamend Neuro (NASDAQ:ALZN), an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

View Alzamend Neuro Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles